ABREVA

This brand name is authorized in Canada.

Active ingredients

The drug ABREVA contains one active pharmaceutical ingredient (API):

`1`	Docosanol UNII `9G1OE216XY` - DOCOSANOL
	The exact mechanism of the antiviral activity of docosanol is unknown. In vitro studies indicate that docosanol affects the fusion between the virus and the plasma membrane, which inhibits intracellular uptake and replication of virus. Docosanol has no effect against non-enveloped viruses.
	Read more about Docosanol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D06BB11	Docosanol	D Dermatologicals → D06 Antibiotics and chemotherapeutics for dermatological use → D06B Chemotherapeutics for topical use → D06BB Antivirals
Discover more medicines within D06BB11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02245677

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.